Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

OBJECTIVES This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil. BACKGROUND There is no cure for PAH, despite effective treatments, and outcomes remain suboptimal. The addition of inhaled treprostinil, a long-acting prostacyclin analog, might be a safe and effective treatment addition to other PAH-specific oral therapies. METHODS Two hundred thirty-five PAH patients with New York Heart Association (NYHA) functional class III (98%) or IV symptoms and a 6-min walk distance (6MWD) of 200 to 450 m while treated with bosentan (70%) or sildenafil were randomized to inhaled treprostinil (up to 54 mug) or inhaled placebo 4 times daily. The primary end point was peak 6MWD at 12 weeks. Secondary end points included time to clinical worsening, Borg Dyspnea Score, NYHA functional class, 12-week trough 6MWD, 6-week peak 6MWD, quality of life, and PAH signs and symptoms. The biomarker N-terminal pro-brain natriuretic peptide (NT-proBNP) was assessed. RESULTS Twenty-three patients withdrew from the study prematurely (13 treprostinil, 10 placebo). The Hodges-Lehmann between-treatment median difference in change from baseline in peak 6MWD was 19 m at week 6 (p = 0.0001) and 20 m at week 12 (p = 0.0004). Hodges-Lehmann between-treatment median difference in change from baseline in trough 6MWD at week 12 was 14 m (p = 0.0066). Quality of life measures and NT-proBNP improved on active therapy. There were no improvements in other secondary end points, including time to clinical worsening, Borg Dyspnea Score, NYHA functional class, and PAH signs and symptoms. Inhaled treprostinil was safe and well-tolerated. CONCLUSIONS This trial demonstrates that, among PAH patients who remain symptomatic on bosentan or sildenafil, inhaled treprostinil improves exercise capacity and quality of life and is safe and well-tolerated. (TRIUMPH I: Double Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension; NCT00147199).

[1]  Gary G. Koch,et al.  Categorical Data Analysis , 2005 .

[2]  A. Torbicki,et al.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.

[3]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[4]  T. Hunt,et al.  Pharmacokinetics and Steady-State Bioequivalence of Treprostinil Sodium (Remodulin®) Administered by the Intravenous and Subcutaneous Route to Normal Volunteers , 2004, Journal of cardiovascular pharmacology.

[5]  M. Pillinger,et al.  Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .

[6]  R. Benza,et al.  Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. , 2006, Chest.

[7]  W. Seeger,et al.  Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.

[8]  Jeffrey L. Anderson,et al.  ACCF/AHA Expert Conseusus Document , 2009 .

[9]  R. Dixon,et al.  Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[10]  Rivka L. Shoulson,et al.  Bloodstream Infections in Patients Given Treatment With Intravenous Prostanoids , 2008, Infection Control & Hospital Epidemiology.

[11]  R. Barst,et al.  FOR THE PRIMARY PULM HYPERTENSION STUDY GROUP. A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 1996 .

[12]  M. Hoeper,et al.  Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension , 2006, European Respiratory Journal.

[13]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[14]  M. Humbert,et al.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.

[15]  R. Benza,et al.  Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. , 2005, American Journal of Respiratory and Critical Care Medicine.

[16]  W. Seeger,et al.  Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. , 2008, Pulmonary pharmacology & therapeutics.

[17]  Donald A. Berry,et al.  Statistical Methodology in the Pharmaceutical Sciences , 1989 .

[18]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[19]  M. Gulati,et al.  Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. , 2005, The American journal of cardiology.

[20]  M. Cheitlin.  Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension: A Randomized Trial , 2009 .

[21]  Orris,et al.  INHALED ILOPROST FOR SEVERE PULMONARY HYPERTENSION , 2002 .

[22]  M. Vogeser,et al.  Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[23]  R. Barst,et al.  Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil , 2006, European Respiratory Journal.

[24]  H. Ghofrani,et al.  Updated evidence-based treatment algorithm in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[25]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[26]  G G Koch,et al.  Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. , 1998, Statistics in medicine.

[27]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[28]  W. Seeger,et al.  Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. , 2006, Journal of the American College of Cardiology.

[29]  B. Wiens,et al.  Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.

[30]  W. Seeger,et al.  Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. , 2006, Journal of the American College of Cardiology.

[31]  R. Barst,et al.  Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.